Shares of Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) have been given an average rating of “Hold” by the five analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $5.50.
A number of equities analysts have recently weighed in on GUTS shares. Wall Street Zen lowered Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Craig Hallum assumed coverage on Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price target on the stock. Weiss Ratings downgraded Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th.
View Our Latest Report on GUTS
Fractyl Health News Roundup
- Negative Sentiment: Bronstein, Gewirtz & Grossman said a class action has been filed against Fractyl Health and certain officers, alleging investor harm. Bronstein Gewirtz Grossman class action announcement
- Negative Sentiment: The complaints and related investor notices allege that Fractyl promoted positive Revita DMR weight-maintenance data for approximately a year before disclosing that an “outlier” REMAIN-1 clinical-trial site skewed the results. Some filings also allege that operational problems at the site were not timely disclosed. SueWallSt Fractyl deadline notice
- Negative Sentiment: Bernstein Liebhard, Pomerantz, Robbins, Levi & Korsinsky and other firms publicized the securities litigation, broadening investor awareness of the allegations. The proposed class generally covers investors who acquired Fractyl securities from January 13, 2025, through January 29, 2026. Pomerantz Fractyl class action announcement Robbins Fractyl shareholder notice
- Neutral Sentiment: Faruqi & Faruqi reminded investors that October 20, 2026 is the deadline to seek appointment as lead plaintiff. These announcements are legal solicitations and do not establish that Fractyl or its officers committed wrongdoing. Faruqi Fractyl lead plaintiff deadline
Fractyl Health Trading Up 5.0%
Shares of Fractyl Health stock opened at $0.59 on Friday. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $2.44. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The company has a market capitalization of $94.04 million, a P/E ratio of -0.67 and a beta of 2.34. The company has a fifty day moving average of $0.71 and a 200 day moving average of $0.68.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. On average, sell-side analysts anticipate that Fractyl Health will post -0.53 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Fractyl Health
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Fractyl Health in the 2nd quarter valued at $1,431,000. Pale Fire Capital SE boosted its holdings in shares of Fractyl Health by 84.5% during the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after purchasing an additional 2,711,103 shares during the last quarter. General Catalyst Group Management LLC bought a new position in shares of Fractyl Health during the 2nd quarter valued at about $3,880,000. Atom Investors LP purchased a new position in shares of Fractyl Health during the fourth quarter valued at about $4,143,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of Fractyl Health during the second quarter valued at about $8,968,058.
Fractyl Health Company Profile
Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company is working to address the underlying biology of these conditions and pursue treatments that may provide more durable benefits than chronic dosing alone.
Fractyl Health’s technologies include the investigational Revita duodenal mucosal resurfacing (DMR) system, an endoscopic procedure designed to alter the lining of the duodenum and potentially improve metabolic control.
Featured Articles
- Five stocks we like better than Fractyl Health
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
